Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers

What Was Tested

This randomized controlled trial paper looks at Angiotensin II.

The purpose of this study was to assess the inhibitory effect of TCV-116, an orally active angiotensin II (Ang II) antagonist, on the pressor action of exogenous Ang II and to determine the compensatory rise in plasma renin activity and Ang II levels.

Who Took Part

According to the abstract, 4 subjects were involved.

The age groups tagged for this paper are adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, single-blind and placebo-controlled study.

The subjects were allocated by chance, so the Angiotensin II group and the comparison group should start out alike.

Blinding on both sides kept the subjects and researchers unaware of who received Angiotensin II.

In this single-blind Angiotensin II study one party knew the assignments and the other did not.

The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.

The methods mention a period of 8 days.

What Was Measured

Topics PubMed links to this paper include Angiotensin II, Angiotensin Receptor Antagonists, Benzimidazoles, Biphenyl Compounds, Blood Pressure, Renin and Tetrazoles.

What This Means in Plain Language

The paper is a randomized, double-blind and single-blind study of Angiotensin II in 4 subjects over 8 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1995 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.